BioCentury
ARTICLE | Company News

Immuneering, Teva deal

August 10, 2015 7:00 AM UTC

Teva will acquire a 51% stake in Immuneering for $45 million. Immuneering analyzes genomic and proteomic data to generate hypotheses and design follow-up studies for compounds in development. Teva wil...